Economic impact of antimicrobial resistance

Emerging Infectious Diseases

Volumn 7, Issue 2, 2001, Pages 286-292

  McGowan Jr , John E ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DRUG CHOICE; DRUG INDUSTRY; DRUG MARKETING; ECONOMIC ASPECT; EDUCATION; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HEALTH CARE SYSTEM; HUMAN; INFECTION CONTROL; INFORMATION SYSTEM; METHODOLOGY; MOTIVATION; PHYSICIAN;

EID: 0035033397     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0702.010228     Document Type: Conference Paper

References (58)

1. Cost considerations in the evaluation of new therapies for gram-positive bacteria
2. Applying economic principles to health care
3. Epidemiology of drug resistance: Implications for a post-antimicrobial era
4. Cost and benefit in perioperative antimicrobial prophylaxis-methods for economic analysis
5. Superbugs: Should antimicrobial drug resistance be included as a cost in economic evaluation?
6. Cost-effectiveness of vancomycin versus cefazolin for perioperative antibiotic prophylaxis in coronary artery bypass graft surgery
7. Dollars and sense: A practical guide to cost analysis for hospital epidemiology and infection control
8. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia
9. The clinical and economic impact of antimicrobial drug resistance on nosocomial bloodstream infections
10. Nosocomial pulmonary infection by antimicrobial-resistant bacteria of patients hospitalized in intensive care units: Risk factors and survival
11. The economic impact of methicillin-resistant Staphylococcus aureus in Canadian hospitals
12. Nosocomial outbreak of ampicillin resistant Enterococcus faecium: Risk factors for infection and fatal outcome
13. A nationwide, multicenter case-control study comparing risk factors, treatment and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia
14. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997
15. Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia
16. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa
17. The economic impact of Staphylococcus aureus infection in New York City hospitals
18. Evaluation of Acinetobacter baumanii infection and colonization and antimicrobial treatment patterns in an urban teaching hospital
19. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms
20. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: At what costs?
21. Pneumonia caused by penicillin-non-susceptible and penicillin-susceptible pneumococci in adults: A case-control study
22. Methicillin-resistant Staphylococcus aureus: Acquisition and risk of death in patients in the intensive care unit
23. Economic impact of resistance in the community
24. Evidence of delays in transferring patients with methicillin-resistant Staphylococcus aureus or vancomycin-resistant Enterococcus to long-term-care facilities
25. Economic evaluations of antibiotic use and resistance-a perspective: Report of Task Force 6
26. Control group selection is an important but neglected issue in studies of antibiotic resistance
27. Pharmacoeconomic analyses - Making them transparent, making them credible
28. The quality of reporting in published cost-utility analyses, 1976-1997
29. Ways and means to influence antimicrobial prescribing in healthcare and its impact on resistance
30. Philip Memorial Lecture: Year 2000 bugs - The end of the antibiotic era?
31. Report of the ASM Task Force on Antibiotic Resistance
32. Guidelines for the prevention of antimicrobial drug resistance in hospitals: Joint statement by the Society for Health Care Epidemiology of America and the Infectious Diseases Society of America
33. Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance?
34. Failure to eradicate vancomycin-resistant enterococci in a university hospital and the cost of barrier precautions
35. Antibiotic cycling and marketing into the 21st century: A perspective from the pharmaceutical industry
36. A novel antimicrobiai agent joins the battle against resistant bacteria
37. Medical Letter. Gatifioxacin and moxifioxacin: Two new fluoroquinolones
38. Indications for pneumococcal vaccine in the era of expanding pneumococcal resistance
39. Acute otitis media caused by antibiotic-resistant Streptococcus pneumoniae in southern Israel: Implication for immunizing with conjugate vaccines
40. Local surveillance of antimicrobial drug resistance
41. Controlling antimicrobial drug resistance: The role of infection control and antimicrobial use
42. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance
43. Drug resistance and nosocomial infections: Epidemiology and prevention strategies
44. Antibiotic dosing - Does one size fit all?
45. Guidelines for the control of methicillin-resistant Staphylococcus aureus
46. Editorial response: Epidemiology of extended-spectrum beta-lactamases
47. Effects of requiring prior authorization for selected antimicrobials; expenditures, susceptibilities, and clinical outcomes
48. Antibiotic resistance - Squeezing the balloon?
49. Practices to improve antimicrobial use at 47 US hospitals: The status of the 1997 SHEA/IDSA position paper recommendations
50. A review of the role of antibiotic policies in the control of antibiotic resistance
51. Bug/drug resistance: Sometimes less is more
52. SHEA conference on antimicrobiai drug resistance
53. An economic perspective on policy to reduce antimicrobial drug resistance